Results of the TRANFORM-OCT trial, announced at the Transcatheter Cardiovascular Therapeutics meeting, show a high rate of strut coverage and low rates of neoatherosclerosis with Boston Scientific Corp.’s Synergy everolimus-eluting coronary stent with a biodegradable polymer.
“TRANSFORM-OCT adds a novel mechanistic dimension to the assessment of new-generation drug-eluting stents, consolidating the understanding that well designed and biocompatible polymers, regardless of whether they are durable or biodegradable, may favorably impact the long-term vascular response of these stents,” explained principal investigator Giulio Guagliumi of the Ospedale Giovanni
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?